

Raashid Ahmed Luqmani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4524453/publications.pdf>

Version: 2024-02-01

158
papers

20,871
citations

34105

52
h-index

9861

141
g-index

160
all docs

160
docs citations

160
times ranked

10398
citing authors

#	ARTICLE	IF	CITATIONS
1	2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis and Rheumatism, 2013, 65, 1-11.	6.7	4,839
2	Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. New England Journal of Medicine, 2010, 363, 211-220.	27.0	1,471
3	EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2016, 75, 1583-1594.	0.9	940
4	Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Annals of the Rheumatic Diseases, 2009, 68, 1827-1832.	0.9	825
5	Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis and Rheumatism, 2005, 52, 2461-2469.	6.7	723
6	Long-term patient survival in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2011, 70, 488-494.	0.9	719
7	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. New England Journal of Medicine, 2017, 376, 1921-1932.	27.0	682
8	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases, 2020, 79, 19-30.	0.9	667
9	Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM - Monthly Journal of the Association of Physicians, 1994, 87, 671-8.	0.5	611
10	EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Annals of the Rheumatic Diseases, 2007, 66, 605-617.	0.9	524
11	Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis and Rheumatism, 1997, 40, 371-380.	6.7	497
12	2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Annals of the Rheumatic Diseases, 2012, 71, 484-492.	0.9	451
13	A disease-specific activity index for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity Score. Arthritis and Rheumatism, 2001, 44, 912-920.	6.7	400
14	Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Annals of the Rheumatic Diseases, 2012, 71, 955-960.	0.9	348
15	Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Annals of the Rheumatic Diseases, 2008, 67, 1004-1010.	0.9	343
16	The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technology Assessment, 2016, 20, 1-238.	2.8	313
17	2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis and Rheumatism, 2012, 64, 943-954.	6.7	273
18	BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology, 2014, 53, 2306-2309.	1.9	246

#	ARTICLE	IF	CITATIONS
19	Granulomatosis with Polyangiitis (Wegener's): An alternative name for Wegener's Granulomatosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 863-864.	6.7	244
20	Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1178-1182.	0.9	217
21	Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 177-184.	0.9	214
22	Nomenclature of Cutaneous Vasculitis. <i>Arthritis and Rheumatology</i> , 2018, 70, 171-184.	5.6	200
23	Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1997, 90, 401-409.	0.5	199
24	BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. <i>Rheumatology</i> , 2010, 49, 2217-2219.	1.9	187
25	The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 344-353.	6.4	182
26	A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. <i>Arthritis Care and Research</i> , 2011, 63, 588-596.	3.4	147
27	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1744-1750.	0.9	139
28	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, e1-e23.	1.9	128
29	Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 704-704.	0.9	106
30	Damage occurs early in systemic vasculitis and is an index of outcome. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1997, 90, 391-399.	0.5	104
31	Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. <i>Rheumatology</i> , 2015, 54, 471-481.	1.9	104
32	Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Rheumatology</i> , 2012, 51, 634-643.	1.9	102
33	The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist. <i>Rheumatology</i> , 2018, 57, 227-235.	1.9	101
34	Diagnosis and management of ANCA associated vasculitis. <i>BMJ: British Medical Journal</i> , 2012, 344, e26-e26.	2.3	100
35	10 Disease assessment and management of the vasculitides. <i>Bailliere's Clinical Rheumatology</i> , 1997, 11, 423-446.	1.0	97
36	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1243-1249.	0.9	93

#	ARTICLE	IF	CITATIONS
37	Development of comprehensive disease assessment in systemic vasculitis. Postgraduate Medical Journal, 2008, 84, 143-152.	1.8	91
38	Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials. Rheumatology, 2011, 50, 2214-2222.	1.9	91
39	Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Rheumatology, 1998, 37, 57-63.	1.9	89
40	A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology, 2011, 50, 899-905.	1.9	89
41	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: A Randomized Controlled Study. Arthritis and Rheumatology, 2019, 71, 952-963.	5.6	82
42	CORRELATION OF BLOOD LEVELS OF SOLUBLE VASCULAR CELL ADHESION MOLECULE-1 WITH DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS AND VASCULITIS. Rheumatology, 1994, 33, 1112-1116.	1.9	78
43	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. Arthritis Care and Research, 2020, 72, 1615-1624.	3.4	77
44	Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia. Annals of the Rheumatic Diseases, 2020, 79, 393-399.	0.9	77
45	Relapses in patients with a systemic vasculitis. The Quarterly Journal of Medicine, 1993, 86, 779-89.	1.0	77
46	Nomenclature and classification of vasculitis – update on the ACR/EULAR Diagnosis and Classification of Vasculitis Study (DCVAS). Clinical and Experimental Immunology, 2011, 164, 11-13.	2.6	76
47	Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Annals of the Rheumatic Diseases, 2009, 68, 1125-1130.	0.9	72
48	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. Arthritis and Rheumatology, 2022, 74, 393-399.	5.6	71
49	Mortality in Wegener's granulomatosis: a bimodal pattern. Rheumatology, 2011, 50, 697-702.	1.9	69
50	Patient-reported Outcomes in Polymyalgia Rheumatica. Journal of Rheumatology, 2012, 39, 795-803.	2.0	64
51	Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care and Research, 2011, 63, 1055-1061.	3.4	63
52	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis. Arthritis and Rheumatology, 2022, 74, 400-406.	5.6	62
53	The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting. QJM - Monthly Journal of the Association of Physicians, 2001, 94, 615-621.	0.5	61
54	Diagnosis of giant cell arteritis. Rheumatology, 2020, 59, iii5-iii16.	1.9	58

#	ARTICLE	IF	CITATIONS
55	Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. <i>RMD Open</i> , 2019, 5, e001020.	3.8	56
56	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020, 59, 487-494.	1.9	56
57	ROS-producing immature neutrophils in giant cell arteritis are linked to vascular pathologies. <i>JCI Insight</i> , 2020, 5, .	5.0	53
58	Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. <i>RMD Open</i> , 2019, 5, e001003.	3.8	52
59	Explaining fatigue in ANCA-associated vasculitis. <i>Rheumatology</i> , 2013, 52, 1680-1685.	1.9	50
60	Giant cell arteritis: Current treatment and management. <i>World Journal of Clinical Cases</i> , 2015, 3, 484.	0.8	50
61	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 386-392.	5.6	50
62	BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. <i>Rheumatology</i> , 2010, 49, 1197-1199.	1.9	49
63	Granulomatosis with Polyangiitis (Wegener's). <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 587-588.	6.1	49
64	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 80-85.	0.9	47
65	Classical versus non-renal Wegener's granulomatosis. <i>The Quarterly Journal of Medicine</i> , 1994, 87, 161-7.	1.0	43
66	BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 2311-2313.	1.9	42
67	Damage Assessment in ANCA-Associated Vasculitis. <i>Current Rheumatology Reports</i> , 2012, 14, 494-500.	4.7	42
68	Pseudoporphyria and Nonsteroidal Antiinflammatory Agents in Children with Juvenile Idiopathic Arthritis. <i>Pediatric Dermatology</i> , 2000, 17, 480-483.	0.9	41
69	Systemic vasculitis--is it time to reclassify?. <i>Rheumatology</i> , 2011, 50, 643-645.	1.9	41
70	The RUDY study: using digital technologies to enable a research partnership. <i>European Journal of Human Genetics</i> , 2017, 25, 816-822.	2.8	39
71	An approach to the diagnosis and management of systemic vasculitis. <i>Clinical and Experimental Immunology</i> , 2010, 160, 143-160.	2.6	38
72	Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Rheumatology</i> , 2014, 53, 953-956.	1.9	38

#	ARTICLE	IF	CITATIONS
73	Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212713.	0.9	38
74	Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9. <i>Journal of Rheumatology</i> , 2009, 36, 2362-2368.	2.0	35
75	Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID-19: A Binational, Registry-Based Cohort Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1713-1719.	5.6	35
76	Assessment of damage in vasculitis: expert ratings of damage. <i>Rheumatology</i> , 2009, 48, 823-827.	1.9	34
77	Pulmonary-renal syndromes: An update for respiratory physicians. <i>Respiratory Medicine</i> , 2011, 105, 1413-1421.	2.9	34
78	Update on the classification of vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 3-17.	3.3	34
79	Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway. <i>Rheumatology</i> , 2020, 59, 2316-2324.	1.9	34
80	Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1475-1482.	0.9	34
81	Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 667-676.	5.6	33
82	The role of neutrophils in rheumatic disease-associated vascular inflammation. <i>Nature Reviews Rheumatology</i> , 2022, 18, 158-170.	8.0	32
83	Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. <i>Journal of Rheumatology</i> , 2005, 32, 2488-95.	2.0	32
84	Current Status of Outcome Measure Development in Vasculitis. <i>Journal of Rheumatology</i> , 2014, 41, 593-598.	2.0	31
85	Clinical features and structured clinical evaluation of vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 31-51.	3.3	31
86	A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis. <i>Rheumatology and Therapy</i> , 2020, 7, 793-810.	2.3	30
87	Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again). <i>Rheumatology</i> , 2006, 45, 649-652.	1.9	28
88	Maternal Stressors, Maternal Wellbeing and Children's Wellbeing in the Context of Juvenile Idiopathic Arthritis. <i>Early Child Development and Care</i> , 2002, 172, 89-98.	1.3	27
89	How to diagnose and treat secondary forms of vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 321-336.	3.3	27
90	Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis. <i>Rheumatology</i> , 2020, 59, 3717-3726.	1.9	26

#	ARTICLE	IF	CITATIONS
91	Cardiovascular involvement in primary systemic vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 419-428.	3.3	24
92	State of the Art in the Treatment of Systemic Vasculitides. <i>Frontiers in Immunology</i> , 2014, 5, 471.	4.8	24
93	Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study. <i>Journal of Rheumatology</i> , 2016, 43, 1085-1092.	2.0	24
94	Outpatient assessment of systemic vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 713-732.	3.3	23
95	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. <i>RMD Open</i> , 2017, 3, e000449.	3.8	23
96	Assessing disease activity in the systemic vasculitides. <i>Current Opinion in Rheumatology</i> , 2002, 14, 23-28.	4.3	22
97	Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. <i>Rheumatology</i> , 2021, 60, 617-628.	1.9	22
98	The impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, 2299-2307.	1.9	21
99	Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?. <i>Annals of the Rheumatic Diseases</i> , 2005, 65, 841-844.	0.9	20
100	The role of biologic therapies in the management of systemic vasculitis. <i>Autoimmunity Reviews</i> , 2006, 5, 273-278.	5.8	19
101	Magnetic resonance angiography versus 18F-fluorodeoxyglucose positron emission tomography in large vessel vasculitis. <i>Autoimmunity Reviews</i> , 2019, 18, 102405.	5.8	19
102	Medical student appraisal of interactive computer-assisted learning programs embedded in a general pathology course. <i>Journal of Pathology</i> , 2000, 191, 462-465.	4.5	18
103	Introduction to, and classification of, the systemic vasculitides. <i>Best Practice and Research in Clinical Rheumatology</i> , 2001, 15, 187-202.	3.3	18
104	Developing multidisciplinary guidelines for the management of early rheumatoid arthritis. <i>Musculoskeletal Care</i> , 2008, 6, 97-107.	1.4	17
105	Long-term damage to the ENT system in Wegener's granulomatosis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2011, 268, 733-739.	1.6	17
106	Maintenance of clinical remission in ANCA-associated vasculitis. <i>Nature Reviews Rheumatology</i> , 2013, 9, 127-132.	8.0	17
107	Optimisation of Cyclophosphamide Therapy in Systemic Vasculitis. <i>Clinical Pharmacokinetics</i> , 1998, 34, 79-90.	3.5	16
108	Pulmonary involvement in primary systemic vasculitides. <i>Rheumatology</i> , 2021, 61, 319-330.	1.9	16

#	ARTICLE	IF	CITATIONS
109	Large vessel vasculitides. <i>Current Opinion in Cardiology</i> , 2012, 27, 578-584.	1.8	15
110	Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss. <i>Rheumatology</i> , 2021, 60, 4361-4366.	1.9	15
111	Treatment of Polymyalgia Rheumatica and Giant Cell Arteritis: Are We Any Further Forward?. <i>Annals of Internal Medicine</i> , 2007, 146, 674.	3.9	14
112	Assessment of systemic vasculitis. <i>Autoimmunity Reviews</i> , 2008, 8, 170-175.	5.8	13
113	Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S162-8.	0.8	13
114	Pharmacotherapy of vasculitis. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1273-1289.	1.8	12
115	Outcome Measures in ANCA-associated Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, 587-607.	1.9	12
116	Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: AANICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2014, 32, 1171-1183.	3.3	12
117	Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?. <i>RMD Open</i> , 2017, 3, e000353.	3.8	12
118	Development of a score for assessment of radiologic damage in large-vessel vasculitis (Combined) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.8	11
119	Evaluation of vasculitis disease activity in Europe. <i>European Journal of Internal Medicine</i> , 2001, 12, 401-402.	2.2	8
120	Disease assessment in systemic vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2015, 30 Suppl 1, i76-82.	0.7	8
121	Cryofibrinogenaemiaâ€”a neglected disease. <i>Rheumatology</i> , 2016, 56, kew379.	1.9	8
122	Clinical Pharmacology and Modification of Autoimmunity and Inflammation in Rheumatoid Disease. <i>Drugs</i> , 1994, 47, 259-285.	10.9	7
123	Is it possible to offer evidence-based treatment for systemic vasculitis?: Editorial review. <i>Scandinavian Journal of Rheumatology</i> , 2000, 29, 211-215.	1.1	7
124	Autoimmune markers for the diagnosis of rheumatoid arthritis in primary care: primary care diagnostic technology update. <i>British Journal of General Practice</i> , 2013, 63, 553-554.	1.4	7
125	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2019, 46, 928-934.	2.0	6
126	Time to focus on outcome assessment tools for childhood vasculitis. <i>Pediatric Rheumatology</i> , 2011, 9, 29.	2.1	4

#	ARTICLE	IF	CITATIONS
127	Clinicopathologic Associations in a Large International Cohort of Patients With Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2022, 74, 1013-1018.	3.4	4
128	Pleural Wegener's granulomatosis: a rare presentation. <i>Histopathology</i> , 2009, 54, 391-393.	2.9	3
129	Making the most of the waiting room: Electronic patient engagement, a mixed methods study. <i>Digital Health</i> , 2018, 4, 205520761775130.	1.8	3
130	Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 569-570.	0.9	2
131	THU0286...MANAGEMENT OF TAKAYASU ARTERITIS: A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS. , 2019, , .		2
132	A hidden lung cancer in a patient with granulomatosis with polyangiitis. <i>BJR case Reports</i> , 2020, 6, 20190114.	0.2	2
133	Response to: "Diagnostic accuracy of novel ultrasonographic halo score for giant cell arteritis: methodological issues" by Ghajari and Sabour. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e106-e106.	0.9	2
134	Measuring disease activity and outcomes in clinical studies.. <i>Cleveland Clinic Journal of Medicine</i> , 2002, 69, S1100-S1100.	1.3	2
135	Early development of new cardiovascular risk factors in the systemic vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 126-134.	0.8	2
136	Polyarteritis Nodosa and Related Disorders. , 2017, , 1559-1570.		1
137	Preface. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 1-2.	3.3	1
138	O35Aortic dissection secondary to giant cell arteritis in a patient on tocilizumab for established seronegative rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, .	1.9	1
139	O50IgG4 related disease causing left anterior descending artery stenosis successfully treated with rituximab therapy. <i>Rheumatology</i> , 2018, 57, .	1.9	1
140	FRI0284...RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS: EVIDENCE TO GUIDE THE MANAGEMENT OF GIANT CELL ARTERITIS. , 2019, , .		1
141	Medical student appraisal of interactive computer-assisted learning programs embedded in a general pathology course. <i>Journal of Pathology</i> , 2000, 191, 462-465.	4.5	1
142	BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. <i>Rheumatology</i> , 2010, , .	1.9	1
143	Polyarteritis Nodosa and Related Disorders. , 2013, , 1498-1507.		1
144	Treatment of vasculitis in rheumatoid arthritis. <i>Annales De Médecine Interne</i> , 1994, 145, 566-76.	0.2	1

#	ARTICLE	IF	CITATIONS
145	The use of ultrasound in the management of large-vessel vasculitis: an evolving concept. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 114, 96-102.	0.8	1
146	P115 Remote clinical management: incorporating electronic assessment of patients with rheumatic diseases into standard clinical pathways and comparison to in-person assessment. <i>Rheumatology</i> , 2022, 61, .	1.9	1
147	Disease assessment in systemic vasculitis. <i>APLAR Journal of Rheumatology</i> , 2004, 7, 150-157.	0.2	0
148	Update on the use of biologics in primary systemic vasculitides. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 901-911.	3.0	0
149	The Need for Diagnostic Criteria in Systemic Vasculitis. <i>Current Immunology Reviews</i> , 2011, 7, 394-401.	1.2	0
150	Recurrent inflammatory stenosis of the M1 segment: diagnostic and therapeutic considerations. <i>Neuroradiology</i> , 2012, 54, 529-532.	2.2	0
151	O18. Early Halo Sign Features on Ultrasound Examination of Treated Patients with Giant Cell Arteritis. <i>Rheumatology</i> , 2015, , .	1.9	0
152	333. THE ROLE OF ULTRASOUND IN THE MANAGEMENT OF GIANT CELL ARTERITIS IN ROUTINE CLINICAL PRACTICE. <i>Rheumatology</i> , 2017, 56, .	1.9	0
153	i128 Improving value projects. <i>Rheumatology</i> , 2018, 57, .	1.9	0
154	Small- and Medium-Vessel Primary Vasculitis. , 2019, , 789-807.e1.		0
155	EP03 An audit of glucocorticoid prescription in patients with giant cell arteritis. <i>Rheumatology</i> , 2020, 59, .	1.9	0
156	Comment on: Diagnosis of giant cell arteritis: reply. <i>Rheumatology</i> , 2020, 59, e119-e121.	1.9	0
157	P211 Aortitis: clinical experience within a tertiary centre. <i>Rheumatology</i> , 2021, 60, .	1.9	0
158	P203 Incidence, characteristics and determinants of severe infections in patients with anti-neutrophil cytoplasm antibody-associated vasculitis receiving rituximab therapy: a single centre study. <i>Rheumatology</i> , 2021, 60, .	1.9	0